On the Hot Seat At Biogen

摘要

JAMES C.MULLEN,THE 46-year-old chief executive of Biogen Idec Inc.,has a degree in chemical engineering-and the demeanor to match.He's an unruffled,just-the-facts-ma'am kind of guy.So when he first learned that Tysabri,his company's breakthrough drug for multiple sclerosis (MS),might be responsible for a deadly brain infection,he moved quickly but calmly to fine out what happened and to make sure it didn't happen again.